Johnson & Johnson (JNJ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Johnson & Johnson stock (JNJ) is currently trading at $237.60. Johnson & Johnson PE ratio is 21.61. Johnson & Johnson PS ratio (Price-to-Sales) is 6.09. Analyst consensus price target for JNJ is $238.29. WallStSmart rates JNJ as Moderate Buy.
Johnson & Johnson (JNJ) stock price prediction for 2030: Base case $218.95. Bull case $273.68. Bear case $164.21. See full JNJ 2030 price forecast and methodology on WallStSmart.
- JNJ PE ratio analysis and historical PE chart
- JNJ PS ratio (Price-to-Sales) history and trend
- JNJ intrinsic value — DCF, Graham Number, EPV models
- JNJ stock price prediction 2025 2026 2027 2028 2029 2030
- JNJ fair value vs current price
- JNJ insider transactions and insider buying
- Is JNJ undervalued or overvalued?
- Johnson & Johnson financial analysis — revenue, earnings, cash flow
- JNJ Piotroski F-Score and Altman Z-Score
- JNJ analyst price target and Smart Rating
Johnson & Johnson
📊 No data available
Try selecting a different time range
JNJ Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Johnson & Johnson (JNJ)
JNJ trades at a significant discount to its Graham intrinsic value of $515.74, offering a 54% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Johnson & Johnson (JNJ) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Johnson & Johnson (JNJ) Key Strengths (6)
Mega-cap company, among the largest in the world
Every $100 of shareholder equity generates $35 in profit
Earnings per share surging 48.60% year-over-year
Keeps $28 of every $100 in revenue as net profit
75.75% of shares held by major funds and institutions
Strong operational efficiency: $24 kept per $100 revenue
Johnson & Johnson (JNJ) Areas to Watch (4)
Very expensive at 7.2x book value
Premium valuation at 6.1x annual revenue
Modest revenue growth at 9.10%
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
Johnson & Johnson (JNJ) Detailed Analysis Report
Overall Assessment
This company scores 71/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.7/10) while 4 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap, Return on Equity, EPS Growth. Profitability is solid with Return on Equity at 35.00%, Operating Margin at 24.00%, Profit Margin at 28.50%. Growth metrics are encouraging with EPS Growth at 48.60%.
The Bear Case
The primary concerns are Price/Book, Price/Sales, Revenue Growth. Some valuation metrics including PEG Ratio (1.70), Price/Sales (6.09), Price/Book (7.19) suggest expensive pricing. Growth concerns include Revenue Growth at 9.10%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 35.00% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 9.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Market Cap and Return on Equity makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Johnson & Johnson (JNJ) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Johnson & Johnson is a mature, profitable business with steady cash generation. Revenue reached 94.2B with 9% growth year-over-year. Profit margins are strong at 28.5%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 3500.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 28.5% and operating margin of 24.0% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Johnson & Johnson.
Bottom Line
Johnson & Johnson is a well-established business delivering consistent profitability with 28.5% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(212 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SCHMID, TIMOTHY EVP, WW Chair, MedTech | Sell | -1,322 |
Data sourced from SEC Form 4 filings
Last updated: 2:56:08 PM
About Johnson & Johnson(JNJ)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.